

Kennedy Joseph T  
Form 4  
April 03, 2018

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Kennedy Joseph T

2. Issuer Name and Ticker or Trading Symbol  
AMARIN CORP PLC\UK [AMRN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
C/O AMARIN PHARMA,  
INC., 1430 ROUTE 206

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/31/2018

\_\_\_ Director \_\_\_ 10% Owner  
 Officer (give title below) \_\_\_ Other (specify below)  
General Counsel

(Street)  
BEDMINSTER, NJ 07921

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_ Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4)                |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|--|
|                                 |                                      |  | Code                           | V   | Amount or Price   |  |  |
| Ordinary Shares <sup>(1)</sup>  | 03/31/2018                           |  | M                              |   | 47,187 <sup>(2)</sup>   | A  | <u>(3)</u> 65,621 <sup>(4)</sup> D               |
| Ordinary Shares <sup>(1)</sup>  | 03/31/2018                           |  | M                              |   | 6,250 <sup>(5)</sup>  | A  | <u>(3)</u> 71,871 <sup>(4)</sup> D               |
| Ordinary Shares <sup>(1)</sup>  | 03/31/2018                           |  | F <sup>(6)</sup>               |   | 26,495  | D  | \$ 3.01 45,376 <sup>(4)</sup> D                  |
| Ordinary Shares <sup>(1)</sup>  | 04/02/2018                           |  | S <sup>(7)</sup>               |   | 7,900   | D  | \$ 2.9139 <sup>(8)</sup> 37,476 <sup>(4)</sup> D |
| Ordinary Shares <sup>(1)</sup>  | 04/03/2018                           |  | S <sup>(7)</sup>               |   | 19,042  | D  | \$ 2.8911 18,434 <sup>(4)</sup> D                |

(9)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. F...                        |                            |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--------------------------------|----------------------------|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title                          | Amount or Number of Shares |
| Restricted Stock Units <sup>(10)</sup>     | \$ 0   | 03/31/2018                           |  | M                              | 47,187  | <u>(2)</u>   | <u>(3)</u>  | Ordinary Shares <sup>(1)</sup> | 47,187                     |
| Restricted Stock Units <sup>(10)</sup>     | \$ 0   | 03/31/2018                           |  | M                              | 6,250   | <u>(5)</u>   | <u>(3)</u>  | Ordinary Shares <sup>(1)</sup> | 6,250                      |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                 |       |
|---|---------------|-----------|-----------------|-------|
|   | Director      | 10% Owner | Officer         | Other |
| Kennedy Joseph T<br>C/O AMARIN PHARMA, INC.<br>1430 ROUTE 206<br>BEDMINSTER, NJ 07921 |               |           | General Counsel |       |

## Signatures

/s/ Joseph T.  
Kennedy

04/03/2018

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

## Edgar Filing: Kennedy Joseph T - Form 4

- (1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.  
As previously reported on July 8, 2015, the Reporting Person was granted 755,000 Restricted Stock Units ("RSUs") under the
- (2) Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in 16 equal quarterly installments. The eleventh vesting event occurred on March 31, 2018.
- (3) Not applicable.
- (4) Please see the section titled "Remarks" below for additional information.
- (5) As previously reported on October 6, 2015, the Reporting Person was granted 100,000 RSUs under the Plan. These RSUs vest in 16 equal quarterly installments. The eleventh vesting event occurred on March 31, 2018.
- (6) Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
- (7) Sales made pursuant to a 10b5-1 trading plan dated December 9, 2016.  
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from
- (8) \$2.87 to \$3.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.  
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from
- (9) \$2.83 to \$2.935, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- (10) Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.

### Remarks:

In the case of a Change of Control (as defined in the Plan), the grants described in this Form 4 vest in full. As of the date of th

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.